Kolexia
Malaurie-Agostini Emmanuelle Oncologie radiothérapie
Malaurie-Agostini Emmanuelle
Oncologie radiothérapie
Centre Hospitalier Intercommunal Créteil
Créteil, France
60 Activités
2 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Tumeurs du sein Carcinomes Carcinome épidermoïde Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou Tumeurs de la trompe de Fallope Adénocarcinome

Collaborateurs

Voir plus
Kaminsky Marie Christine
Kaminsky Marie Christine
Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
Berton Dominique
Berton Dominique
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Lortholary Alain
Lortholary Alain
Alek Onco, Nantes, France
Dubot Coraline
Dubot Coraline
Centre François-Baclesse, Caen, France

Industries

Voir plus
AstraZeneca
7 collaboration(s)
Dernière en 2023
MSD
4 collaboration(s)
Dernière en 2023
Janssen
3 collaboration(s)
Dernière en 2023
B3TSI
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
CHIVA: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecologic oncology   02 juin 2023
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecologic oncology   01 mars 2023
59P Expression of CD47 a potent ‘don’t eat me signal' in ovarian cancer (OC): Correlation with other immune features and evolution under neoadjuvant chemotherapy (NACT), a GINEGEPS study
Abstract Book of the ESMO Gynaecological Cancers Congress, Barcelona, Spain, 23-24 February 2023   01 février 2023
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecologic oncology   25 janvier 2023
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).
European journal of cancer (Oxford, England : 1990)   09 novembre 2022
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
JAMA oncology   11 mars 2022
Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients.
Frontiers in pharmacology   20 septembre 2021
BIBW2992ORL: A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
Essai Clinique (Boehringer Ingelheim)   28 mai 2021
Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.
2021 ASCO Annual Meeting I   28 mai 2021